Sickle cell disease (SCD) comprises a group of inherited red blood cell disorders that often leads to early death. However, increased survival among children with the disease has led to a significant clinical and economic burden in adult patients as the morbidity and mortality caused by end-organ damage has shifted from childhood to adulthood. This research report uses real-world medical and pharmacy claims data to quantify the changes in morbidity, healthcare utilization, and costs driven by the evolving clinical needs of SCD patients as they age.
This paper was commissioned by the Global Blood Therapeutics.
